Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 804 results for "genentech"

Genentech files NDA for cobimetinib with Zelboraf in advanced melanoma15-12-2014
Pharma Letter

Genentech Announces Top-line Results Of Phase III MARIANNE Trial

Genentech, a member of the Roche Group (RHHBY.PK,ROG.SW,RO.SW) reported top-line results of the Phase III MARIANNE study. The trial evaluated three HER2-targeted regimens - Kadcyla plus Perjeta, Kadcyla alone, and Herceptin plus taxane chemotherapy ..., 6 hours ago

57 images for genentech

Bidness Etc, 3 days ago
Pharma Letter, 3 days ago
Bio Spectrum Asia, 2 days ago
Business Recorder, 4 days ago, 3 days ago
Tech Times, 3 days ago, 4 days ago
Waynesville Daily Guide, 1 week ago
San Francisco Business Times, 6 days ago
Business Insider, 1 week ago

Roche's early development head to retire

Head of Roche's Genentech Research and Early Development (gRED) unit, Richard Scheller, is to step down and retire at the end of 2014. Scheller will be replaced by the current head of small molecule drug discovery at Genentech, Michael Varney. He ...
 Pharma Field21 hours ago Roche says head of Genentech research unit to retire  CNBC1 week ago Genentech R&D chief Richard Scheller to retire  Fat Pitch Financials6 days ago Genentech's R&D chief to retire, Roche names successor  FirstWord Pharma6 days ago
Bidness Etc

Genentech Files NDA For Skin Cancer Treatment

Genentech, a US-based biotech subsidiary of Roche Holding Ltd. (ADR) ( OTCMKTS:RHHBY ), announced Monday that it has filed a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for its pipeline drug, cobemetinib. Cobemetinib ...
 Bidness Etc3 days ago Pharmacists Pan Genentech Distribution Model  ASHP3 days ago Roche's Genentech Seeks Approval for Skin Cancer Drug  Austin American Statesman4 days ago Roche biotech unit submits skin cancer drug application to U.S. regulator  Reuters4 days ago
Bio Spectrum Asia

Ex-Genentech oncology head joins Gilead

 Bio Spectrum Asia2 days ago Gilead secures senior head from Genentech  Pharmafocus2 days ago Gilead Sciences, Inc. Poaches Genentech Exec To Head Cancer Drug Program  BioSpace3 days ago

EXELIXIS' : Collaborator Genentech Completes Filing of New Drug Application for Cobimetinib

Exelixis reported its collaborator Genentech has completed the filing of its New Drug Application with the U.S. Food and Drug Administration for cobimetinib, a specific MEK inhibitor discovered by Exelixis , in combination with vemurafenib for ...
 4 Traders2 days ago Exelixis' Collaborator Genentech Completes Filing of New Drug Application for Cobimetinib  Individual.com2 days ago Lundbeck scraps stroke drug  Pharmafocus1 day ago

Roche Names New Genentech Chief

By Neil MacLucas ZURICH-- Roche Holding AG said Friday it plans to expand its board of directors by two members, as it announced the head of its important Genentech research and development arm will retire. Basel-based Roche said it will ...
 4 Traders1 week ago Roche Names New Genentech R&D Chief  ADVFN India1 week ago

Merck Pays $110M for Cancer Drug Group OncoEthix

The deal follows cancer treatment M&A from Genentech and Celsion December 18, 2014 Merck (NYSE: MRK) has acquired a Swiss cancer drug development company, OncoEthix , for $110 million. OncoEthix is developing an oral bromodomain inhibitor, ...
 Mergers & Acquisitions17 hours ago

Genentech's Lucentis dubbed 'breakthrough' in diabetic retinopathy

GMT 2014 Informa plc. All rights reserved. This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT ...
 Scrip1 day ago FDA Breakthrough Status For Genentech's Lucentis  BioSpace2 days ago Genentech receives FDA breakthrough therapy designation for Lucentis  Orthopedics Today3 days ago Doctors Who Promote More Expensive Eye Drug Are Among The Highest-Paid Genentech (RHHBY) Consultants 12/10/2014  ClinicSpace1 week ago

Phigenix, Inc. v. Genentech, Inc. and Immunogen, Inc.: IPR2014-00842, Denying Institution IPR2014-00842

Takeaway: A petitioner must provide evidence showing why each and every element of the claims would have been obvious when presenting a ground of unpatentability based on obviousness. Merely stating that a feature would have been obviously taught by ...
 National Law Review21 hours ago

Roche Submitted NDA for Melanoma Combination Drug - Analyst Blog

Roche's ( RHHBY ) subsidiary Genentech and its partner Exelixis, Inc. ( EXEL ) announced that Roche has submitted a new drug application (NDA) in the U.S. for the use of cobimetinib plus Zelboraf in treatment-naive patients with unresectable locally ...
 Zacks.com2 days ago Roche wins drug discovery award for Gazyvaro  Pharmafocus1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less